Evidence map›Paper›PMID 34025422›Full record

ArticleFrontiers in pharmacology2021

Effects of a Common Eight Base Pairs Duplication at the Exon 7-Intron 7 Junction on Splicing, Expression, and Function of OCT1.

Sarah Römer, Marleen J Meyer, Kathrin Klein, Lennart V Schneider, Johannes Matthaei, Ana Tzvetkova, Joanna Łapczuk-Romańska, Jochen Gaedcke, Marek Droździk, Jürgen Brockmöller and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Effects ofFrontiers in bioengineering and biotechnology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Sarah RömerInstitute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
Marleen J MeyerInstitute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
Kathrin KleinDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Lennart V SchneiderInstitute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany.
Johannes MatthaeiInstitute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany.
Ana TzvetkovaInstitute of Bioinformatics, University Medicine Greifswald, Greifswald, Germany.
Joanna Łapczuk-RomańskaDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland.
Jochen GaedckeDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany.
Marek DroździkDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland.
Jürgen BrockmöllerInstitute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany.
Anne T NiesDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Mladen V TzvetkovInstitute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
Universitätsmedizin Greifswald · DEPomeranian Medical University · PLUniversitätsmedizin Göttingen · DEUniversity of Göttingen · DEDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organic cation transporter 1 (OCT1, SLC22A1) is localized in the sinusoidal membrane of human hepatocytes and mediates hepatic uptake of weakly basic or cationic drugs and endogenous compounds. Common amino acid substitutions in OCT1 were associated with altered pharmacokinetics and efficacy of drugs like sumatriptan and fenoterol. Recently, the common splice variant rs35854239 has also been suggested to affect OCT1 function. rs35854239 represents an 8 bp duplication of the donor splice site at the exon 7-intron 7 junction. Here we quantified the extent to which this duplication affects OCT1 splicing and, as a consequence, the expression and the function of OCT1. We used pyrosequencing and deep RNA-sequencing to quantify the effect of rs35854239 on splicing after minigene expression of this variant in HepG2 and Huh7 cells and directly in human liver samples. Further, we analyzed the effects of rs35854239 on OCT1 mRNA expression in total, localization and activity of the resulting OCT1 protein, and on the pharmacokinetics of sumatriptan and fenoterol. The 8 bp duplication caused alternative splicing in 38% (deep RNA-sequencing) to 52% (pyrosequencing) of the minigene transcripts when analyzed in HepG2 and Huh7 cells. The alternatively spliced transcript encodes for a truncated protein that after transient transfection in HEK293 cells was not localized in the plasma membrane and was not able to transport the OCT1 model substrate ASP

Indexed as

allelic expression imbalance (AEI)fenoterolins/del variantminigeneorganic cation transporter 1pharmacokineticsSLC22A1sumatriptan

Identifiers

PMID34025422
PMCPMC8137991
OpenAlexW3158406950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.